Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive therapy targets stubborn leukemia in early trial

NCT ID NCT06356922

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive drug called [177Lu]Lu-PentixaTher in people with acute leukemia that has come back or not responded to standard treatments. The drug seeks out and delivers radiation directly to leukemia cells that have a specific marker (CXCR4). The main goals are to find the safest dose and see if it can shrink the cancer. About 21 adults will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU d'Angers

    RECRUITING

    Angers, Maine et Loire, 49100, France

    Contact Email: •••••@•••••

  • CHU de Bordeaux

    RECRUITING

    Bordeaux, Gironde, 33604, France

    Contact

    Contact

  • CHU de Clermont-Ferrand

    RECRUITING

    Clermont-Ferrand, Puy de Dôme, 63000, France

    Contact Email: •••••@•••••

  • CHU de Nantes

    RECRUITING

    Nantes, Loire-Atlantique, 44000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.